Abeona Signs a License and Inventory Purchase Agreements with Taysha for ABO-202 to Treat CLN1 Disease (Infantile Batten disease)

 Abeona Signs a License and Inventory Purchase Agreements with Taysha  for ABO-202 to Treat CLN1 Disease (Infantile Batten disease)

Abeona Therapeutics Signs a License and Inventory Purchase Agreements with Taysha Gene Therapies for ABO-202 to Treat CLN1 Disease (Infantile Batten disease)

Shots:

  • Abeona to receive $7M including $3M up front, $4M inventory purchase price, including GMP-sourced CLN1 plasmid and is eligible to receive $56M as clinical, regulatory, and commercial milestones along with royalties on sales of ABO-202
  • Taysha gets an exclusive WW right to IP developed by scientists at the UNC and Abeona and Abeona know-how relating to the research, development, and manufacture of ABO-202. Abeona will continue the development of the P-I/II clinical trial protocol and manufacturing process and has received FDA clearance of its IND application that is anticipated to enter the clinic in 2021
  • ABO-202 is a novel, one-time gene therapy for CLN1 disease, designed to deliver a functional copy of the PPT1 gene and has received the US FDA’s ODD, RPD and EMA’s OMPD

Click here ­to­ read full press release/ article | Ref: Abeona Therapeutics | Image: Pexel

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post